Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C]-Rongliflozin in Healthy Male Participants
NCT05109078Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Dec 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rongliflozin in type 2 diabetes mellitus (T2DM), sponsored by Sunshine Lake Pharma. Primary endpoints: Cumulative excretion of 14C-labeled drug-related material at 14 days, Proportion of different metabolites at 14 days and 1 more. Started Dec 2021; status: completed.
02
Drugs
rongliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05109078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05109078.